{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:40:31Z","timestamp":1777894831977,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jmii.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:48:54Z","timestamp":1752608934000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced humoral and cellular immunogenicity of COVID-19 vaccines in people living with HIV: A real-world analysis"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6266-1793","authenticated-orcid":false,"given":"Tzu-Ping","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-4206","authenticated-orcid":false,"given":"Ming-Chi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-1052","authenticated-orcid":false,"given":"Po-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-7861","authenticated-orcid":false,"given":"Ching-Lung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-9134","authenticated-orcid":false,"given":"Jia-Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-842X","authenticated-orcid":false,"given":"Nan-Yao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10249","key":"10.1016\/j.jmii.2025.06.013_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jmii.2025.06.013_bib3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.06.013_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jmii.2025.06.013_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104661","article-title":"Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV-a prospective observational cohort study","volume":"93","author":"Heftdal","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jmii.2025.06.013_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac089","article-title":"SARS-CoV-2 humoral and cellular immune responses of patients with HIV after vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv Medical Center","volume":"9","author":"Tau","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2025.06.013_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2022.10.005","article-title":"Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis","volume":"124","author":"Yin","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2025.06.013_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jmii.2022.04.006","article-title":"Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak","volume":"55","author":"Lin","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"issue":"6 Pt 1","key":"10.1016\/j.jmii.2025.06.013_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jmii.2022.09.004","article-title":"Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea","volume":"55","author":"Widyasari","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"issue":"8","key":"10.1016\/j.jmii.2025.06.013_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/clinchem\/hvaa131","article-title":"Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies","volume":"66","author":"Favresse","year":"2020","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.013_bib17","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","article-title":"Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)","volume":"9","author":"Meyer","year":"2020","journal-title":"Emerg Microb Infect"},{"issue":"9","key":"10.1016\/j.jmii.2025.06.013_bib18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jmii.2025.06.013_bib19","article-title":"Effects of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jmii.2025.06.013_bib20","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/vaccines10091569","article-title":"Immunogenicity and safety of COVID-19 vaccines among people living with HIV: a systematic review and meta-analysis","volume":"10","author":"Kang","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.013_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s43856-023-00245-5","article-title":"B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV","volume":"3","author":"Polvere","year":"2023","journal-title":"Commun Med"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.013_bib25","doi-asserted-by":"crossref","first-page":"e916","DOI":"10.1093\/cid\/ciab1009","volume":"75","author":"Spinelli","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jmii.2025.06.013_bib35","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.jmii.2025.06.013_bib36","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2025.06.013_bib40","unstructured":"HIV treatment as prevention. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hivpartners\/php\/hiv-treatment\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/hiv\/risk\/art\/index.html. 17, January, 2025."},{"key":"10.1016\/j.jmii.2025.06.013_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2024.02.004","article-title":"Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV","author":"Liu","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"10.1016\/j.jmii.2025.06.013_bib21","article-title":"Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV","volume":"8","author":"Liu","year":"2022","journal-title":"J Virus Erad"},{"issue":"6","key":"10.1016\/j.jmii.2025.06.013_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jmii.2025.06.013_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/ciac803","article-title":"Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial","volume":"76","author":"Heath","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.06.013_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2022.11.022","article-title":"Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens","volume":"126","author":"Kanokudom","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"13","key":"10.1016\/j.jmii.2025.06.013_bib39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jmii.2025.06.013_bib28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jmii.2025.06.013_bib30","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jmii.2025.06.013_bib31","first-page":"1493","article-title":"Durability and immunogenicity of neutralizing antibodies response against Omicron variants after three doses of subunit SARS-CoV-2 vaccine MVC-COV1901: an extension to an open-label, dose-escalation phase 1 study","volume":"11","author":"Hsieh","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.013_bib32","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1038\/s41467-022-33146-7","article-title":"A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jmii.2025.06.013_bib33","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","article-title":"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study","volume":"3","author":"Barin","year":"2022","journal-title":"Lancet Microbe"},{"issue":"12","key":"10.1016\/j.jmii.2025.06.013_bib34","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/vaccines9121458","article-title":"COVID-19 vaccination in people living with HIV (PLWH) in China: a cross sectional study of vaccine hesitancy, safety, and immunogenicity","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"26","key":"10.1016\/j.jmii.2025.06.013_bib37","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"Covid-19 vaccine immunogenicity in people living with HIV-1","volume":"40","author":"Nault","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.013_bib38","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1093\/cid\/ciac238","volume":"75","author":"Antinori","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jmii.2025.06.013_bib42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiab593","article-title":"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines","volume":"225","author":"Naranbhai","year":"2022","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jmii.2025.06.013_bib22","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:34:03Z","timestamp":1777620843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1684118225001343"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.06.013","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced humoral and cellular immunogenicity of COVID-19 vaccines in people living with HIV: A real-world analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}